News & Trends - MedTech & Diagnostics
Is government’s $6.5 billion private health insurance injection failing to ease the public system burden

MedTech & Diagnostics News: With an annual injection of $6.5 billion by the government in rebates to encourage Australians to opt for private health insurance, along with an extra $6.1 billion allocated for services provided in private hospitals, concerns about the value of private health insurance continues to be raised.
Non-urgent or elective surgery has a waiting list in public hospitals. State governments manage waiting times in public hospitals directly. At the federal level, Australia has largely emphasised the role of private healthcare as the main mechanism for shifting demand away from the overburdened public hospital system.
While private patients have the advantage of more flexibility in selecting their care, whether in private hospitals or as private patients within public hospitals, and the freedom to choose attending physicians as well as access to superior amenities including private rooms, they often encounter out-of-pocket expenses. These expenses arise from insurance deductibles and gap payments, which result from disparities between what insurers cover and the fees charged by doctors.
Within the complex landscape of healthcare systems, the challenge of balancing accessibility, efficiency, and cost-effectiveness persists. Waiting times for publicly funded elective procedures emerge as a critical issue, with prolonged waits posing risks to patient well-being and satisfaction, as well as potentially increasing overall medical costs.
Supporters of the government’s approach argue that increasing private health insurance uptake could ease pressure on the public system, potentially leading to reductions in wait times for medical procedures. However, a recent study has cast doubt on this assertion.
A recent study revealed limited impact of increasing private health insurance uptake on reducing wait times in public hospitals, with a marginal decrease of 0.34 days (or 0.5%) observed on average. While the effects vary across different medical specialties and age groups, “the practical significance of this effect is limited, if not negligible”, the authors wrote.
Responding to these findings, the study’s authors advocate for a re-evaluation of healthcare policy, emphasising investment in alternative approaches.
“Our findings suggest that policy interventions targeting at increasing PHI take-up will not have meaningful effect on reducing elective surgery waiting times. Instead, the government should consider other approaches, for example, investing in innovative care delivery and funding models, strengthening community health services and community-based care, chronic disease prevention in primary care, or even purchasing services directly from private hospitals,” the authors wrote.
Policymakers are urged to address broader systemic issues. Structural reforms, including adjustments to funding and governance arrangements, are cited as essential steps in tackling the underlying challenges faced by the health system. Regional issues further complicate the landscape, with concerns ranging from health workforce shortages to the fragmentation of care and imbalances in matching healthcare capacity with regional needs.
“Alternative policies aiming at improving the efficiency of public hospitals and advancing equitable access to care should be a priority for policymakers,” the authors concluded.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

New combination therapy improves survival rates for Aussies with advanced prostate cancer
A world-first treatment approach has demonstrated significant advancements in the management of metastatic castration-resistant prostate cancer (mCRPC) compared to conventional […]
MoreNews & Trends - Pharmaceuticals

‘Don’t just learn what illness is, learn what it feels like,’ Dr Ben Bravery
With the iconic Sydney Harbour as a backdrop, the Merck Healthcare team came together for a dynamic and engaging kick-off […]
MoreNews & Trends - MedTech & Diagnostics

GE HealthCare, Lumus Imaging and GenesisCare unite to bring advanced technology to patients
GE HealthCare and Lumus Imaging have joined forces to enhance medical care in Sydney’s Campbelltown region, unveiling a state-of-the-art imaging […]
MoreNews & Trends - MedTech & Diagnostics

World-First mobile CT for regional healthcare
An Australian X-ray technology company developing a world-first full-body mobile CT following the award of an up to US$16.4m (A$25m) […]
More